research findings provide considerable support that there is still significant potential to discover new
affordable, safe, and efficacious 4-aminoquinoline antimalarials. In present study, new side chain modi-
fied 4-aminoquinoline derivatives and quinoline–acridine hybrids were synthesized and evaluated
in vitro against NF 54 strain of Plasmodium falciparum. Among the evaluated compounds, compound
17 (MIC = 0.125 lg/mL) was equipotent to standard drug CQ (MIC = 0.125 lg/mL) and compound 21
(MIC = 0.031 lg/mL) was four times more potent than CQ. Compound 17 showed the curative response
to all the treated swiss mice infected with CQ-resistant N-67 strain of Plasmodium yoelii at the doses
50 mg/kg and 25 mg/kg for four days by intraperitoneal route and was found to be orally active at the
dose of 100 mg/kg for four days. The promising antimalarial potency of compound 17 highlights the sig-
nificance of exploring the privileged 4-aminoquinoline class